Articles Delivering pharma innovation: Takeda and Novo Nordisk on the... Andrew McConaghie reviews the findings of the latest pharma ranking index, which assesses on the premise: if you gave the same molecule to two different companies in early phase, which would ma
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
